NEW YORK (GenomeWeb) – Biodesix said today that its has received a positive coverage decision from Aetna for its VeriStrat test for guiding therapy in patients with non-small cell lung cancer (NSCLC).

According to Biodesix, Aetna has deemed VeriStrat, which uses MALDI mass spec-based proteomic signatures to identify patients likely to respond to treatment with EGFR inhibitors, medically necessary for patients with advanced NSCLC whose tumors were without EGFR and anaplastic lymphoma kinase mutations.

Aetna has approximately 46 million members in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.

In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.

The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.